Researchers from the department of dermatology at Yale University School of Medicine announced today that they successfully regrew a full head of hair in a patient suffering from alopecia universalis using a drug normally reserved for the treatment of rheumatoid arthritis.

Unlike androgenic alopecia (male pattern hair loss), which is caused by a sensitivity to dihydrotestosterone (DHT) hormone, alopecia universalis is believed to be an “autoimmune alopecia.” An autoimmune disease occurs when the immune system – which normally protects the body from diseases – becomes overactive and attacks the body’s own tissues. When the immune system inappropriately attacks joints, it causes rheumatoid arthritis. When it attacks hair follicles, it causes autoimmune alopecias like alopecia areata, alopecia totalis, and alopecia universalis.

When a patient presented to the Yale department of dermatology with a complaint of a complete absence of all scalp and body hair, or alopecia universalis, the medical team had an interesting idea: why not try to treat this autoimmune disease with a medication proven to treat another autoimmune disease? The team did just that, and started the patient on a rheumatoid arthritis drug called Tofacitinib citrate. Within 2 months, the patient began to show regrowth of scalp and beard hair that previously had not grown for seven years. Encouraged, the team increased the medication, and by 8 months the patient regrew his eyelashes, eyebrows, armpit hair, facial hair, and completely restored his scalp hair.

According to the research team: “The results are exactly what we hoped for. This is a huge step forward in the treatment of patients with alopecia universalis. While it’s one case, we anticipated the successful treatment of this man based on our current understanding of the disease and the drug.” The research team submitted a proposal for a trial of a Tofacitinib citrate cream to treat autoimmune alopecia, and they hope the future study will help other patients use the drug. “There are no good options for long-term treatment of alopecia universalis” said the dermatology researchers. “We believe the same results will be duplicated in other patients, and we plan to try.”

While the drug isn’t likely to have effect in androgenic alopecia patients, it is definitely exciting news for those suffering from autoimmune alopecias!
_________________
Blake Bloxham – formerly “Future_HT_Doc”

Editorial Assistant and Forum Co-Moderator for the Hair Transplant Network, the Hair Loss Learning

Center, the Hair Loss Q&A Blog, and the Hair Restoration Forum

Follow our community on Twitter

Watch hair transplant videos on YouTube

Technorati Tags: , , , hair loss, , , , , ,

Bill - Seemiller

View Comments

  • Mehdi,

    The hair growth potential of Tofacitinib citrate has only just been discovered and is still begin invest aged. To my knowledge, it has only been tested on a single patient with alopecia universalis. Though the results were good, no information has been released to show that these results are consistent or applicable to other forms of hair loss.

    David

  • Hi,I lost some part of my hair by lichen planus, so my question is : does this drug can help to return hairs which effected by lichen planus?

Recent Posts

Body Hair Transplants Are They Worth It? Dr. Pradeep Sethi Answers

I'm at thirty-one year old man with a Norwood 6 level of hair loss. I…

3 years ago

Can I Get an FUE Without Propecia?

I'm a 31 year old male I have been losing hair for the past six…

3 years ago

Am I Balding? How To Tell The Signs of Hair Loss

I'm concerned that i'm going bald. My dad is 54 years old, and still has…

3 years ago

Should I Choose an FUE or FUT Hair Transplant?

I'm a 30-year old male with a Norwood 4 hair loss pattern. I have been…

3 years ago

Should I Get A Hair Transplant or Hair System?

I'm twenty years old and already have aggressive hair loss. I'm imbetween a Norwood 5…

3 years ago

What Is The Success Rate of Hair Transplants?

I'm interested in getting a hair transplant later this year, but I am a very…

3 years ago